Showing 6231-6240 of 20418 results for "".
- Alopecia Areata: Evaluation of Patient-Reported Outcome Measureshttps://reachmd.com/news/alopecia-areata-evaluation-of-patient-reported-outcome-measures/2474185/Within the domain of dermatology, particularly concerning disorders like alopecia areata, it is imperative for clinicians and researchers to grasp both the advantages and drawbacks of diverse patient-reported outcome measures (PROMs). A systematic review detected c
- The Aesthetic Foundation Appoints Dr. Patricia A. McGuire New Presidenthttps://reachmd.com/news/the-aesthetic-foundation-appoints-dr-patricia-a-mcguire-new-president/2475340/The Aesthetic Foundation recently announced the appointment of Patricia A. McGuire, MD, as its new president. Dr. McGuire is a board-certified plastic surgeon and breast surgery specialist. The Aesthetic Foundation said in a press release she brings “decades of experience in patient-cente
- Unlocking the Genetic Mysteries of PHTS-Related Vascular Malformationshttps://reachmd.com/news/unlocking-the-genetic-mysteries-of-phts-related-vascular-malformations/2473867/The exploration of PHTS and its associated vascular malformations is advancing rapidly as genetic discoveries elucidate how changes in cell development, tissue growth, and migration can lead to critical clinical issues. Researchers are increasingly aware that genet
- Revolutionizing Cancer Diagnostics: The Promise of Laser-Based Techniqueshttps://reachmd.com/news/revolutionizing-cancer-diagnostics-the-promise-of-laser-based-techniques/2473850/Explore how innovative laser-based diagnostics dramatically enhance the speed and accuracy of detecting cancerous cells. By integrating cutting-edge laser technology, these methods enable earlier intervention, significantly improving patient care.
- Rituximab Efficacious for Epidermolysis Bullosa Acquisita: Analysishttps://reachmd.com/news/rituximab-shows-promise-for-epidermolysis-bullosa-acquisita/2473835/Data from a new systematic review indicate rituximab (RTX) may potentially be an effective treatment option for epidermolysis bullosa acquisita (EBA). Due to its chronic nature, management of EBA remains challenging, with remission and flare-up
- Hidden Deficiencies: Understanding Vitamin C Deficiency in Hospital Settingshttps://reachmd.com/news/hidden-deficiencies-understanding-vitamin-c-deficiency-in-hospital-settings/2471833/Recent findings confirm that a substantial percentage of hospitalized patients are affected by Vitamin C deficiency, underscoring the critical need for nutritional assessments and early, targeted interventions in hospital care. Overview: A Sile
- Refining the Evaluation of Femoral Torsion: A Comparative Analysis of Measurement Techniqueshttps://reachmd.com/news/refining-the-evaluation-of-femoral-torsion-a-comparative-analysis-of-measurement-techniques/2471843/Background and Clinical Relevance Recent advances in imaging and orthopedic diagnostics have prompted a re-evaluation of how femoral torsion is measured. Traditional reliance on the femoral anteversion angle is increasingly being questioned, as emerging ev
- Unraveling Genetic Clues: Rare Loss-of-Function Variants and Bipolar Disorderhttps://reachmd.com/news/unraveling-genetic-clues-rare-loss-of-function-variants-and-bipolar-disorder/2471838/Innovative research has pinpointed rare loss-of-function variants in HECTD2 and AKAP11 as significantly associated with an increased risk of bipolar disorder. These genetic modifications interfere with essential regulatory pathways pivotal to normal cellular operat
- Advancements and Challenges in Biologic Therapies for Arthritishttps://reachmd.com/news/advancements-and-challenges-in-biologic-therapies-for-arthritis/2471814/Biologic therapies have revolutionized the management of arthritis, offering new avenues for intervention. This article examines biologic DMARDs such as abatacept, golimumab, and sarilumab, focusing on their mechanisms, challenges, and patient response variability in the dy
- Targeting Piezo2: A Promising Strategy to Combat Pulmonary Fibrosishttps://reachmd.com/news/targeting-piezo2-a-promising-strategy-to-combat-pulmonary-fibrosis/2471842/Unlocking a New Frontier in Fibrosis Treatment: The Promise of Piezo2 Inhibition Emerging research demonstrates that inhibiting the Piezo2 receptor could mitigate the mechanical stress‐induced pathways contributing to lung tissue scarring, offering a groundbreaking